Covance, Inc. (NYSE:CVD)

CAPS Rating: 4 out of 5

A drug development services company providing a range of early stage and late stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries.

Recs

0
Player Avatar EMG114 (< 20) Submitted: 5/8/2008 8:27:00 PM : Outperform Start Price: $85.90 CVD Score: -45.23

Good investment for the long-term...

Featured Broker Partners


Advertisement